Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 8 |
| List of Tables | 8 | 1 |
| List of Figures | 9 | 1 |
| Introduction | 10 | 1 |
| Global Markets Direct Report Coverage | 10 | 1 |
| Relapsing Remitting Multiple Sclerosis (RRMS) Overview | 11 | 1 |
| Therapeutics Development | 12 | 2 |
| Pipeline Products for Relapsing Remitting Multiple Sclerosis (RRMS) Overview | 12 | 1 |
| Pipeline Products for Relapsing Remitting Multiple Sclerosis (RRMS) Comparative Analysis | 13 | 1 |
| Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics under Development by Companies | 14 | 2 |
| Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics under Investigation by Universities/Institutes | 16 | 1 |
| Relapsing Remitting Multiple Sclerosis (RRMS) Pipeline Products Glance | 17 | 3 |
| Late Stage Products | 17 | 1 |
| Clinical Stage Products | 18 | 1 |
| Early Stage Products | 19 | 1 |
| Relapsing Remitting Multiple Sclerosis (RRMS) Products under Development by Companies | 20 | 2 |
| Relapsing Remitting Multiple Sclerosis (RRMS) Products under Investigation by Universities/Institutes | 22 | 1 |
| Relapsing Remitting Multiple Sclerosis (RRMS) Companies Involved in Therapeutics Development | 23 | 27 |
| AB Science SA | 23 | 1 |
| AbbVie Inc | 24 | 1 |
| Actelion Ltd | 25 | 1 |
| Alkermes Plc | 26 | 1 |
| Amarna Therapeutics B.V. | 27 | 1 |
| Antisense Therapeutics Limited | 28 | 1 |
| Biocon Limited | 29 | 1 |
| Biogen Inc | 30 | 1 |
| Cognosci, Inc. | 31 | 1 |
| Coherus BioSciences, Inc. | 32 | 1 |
| Forward Pharma A/S | 33 | 1 |
| GeNeuro SA | 34 | 1 |
| GlaxoSmithKline Plc | 35 | 1 |
| Iltoo Pharma | 36 | 1 |
| LFB S.A. | 37 | 1 |
| Mapi Pharma Ltd. | 38 | 1 |
| MedImmune, LLC | 39 | 1 |
| Merck KGaA | 40 | 1 |
| Mitsubishi Tanabe Pharma Corporation | 41 | 1 |
| Neurotec Pharma SL | 42 | 1 |
| Novartis AG | 43 | 1 |
| Octapharma AG | 44 | 1 |
| Opexa Therapeutics, Inc. | 45 | 1 |
| RedHill Biopharma Ltd. | 46 | 1 |
| Teva Pharmaceutical Industries Ltd. | 47 | 1 |
| Xenetic Biosciences (UK) Limited | 48 | 1 |
| Zydus Cadila Healthcare Limited | 49 | 1 |
| Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics Assessment | 50 | 14 |
| Assessment by Monotherapy Products | 50 | 1 |
| Assessment by Combination Products | 51 | 1 |
| Assessment by Target | 52 | 4 |
| Assessment by Mechanism of Action | 56 | 4 |
| Assessment by Route of Administration | 60 | 2 |
| Assessment by Molecule Type | 62 | 2 |
| Drug Profiles | 64 | 109 |
| (clarithromycin + clofazimine + rifabutin) Drug Profile | 64 | 7 |
| aldesleukin Drug Profile | 71 | 1 |
| ALKS-8700 Drug Profile | 72 | 2 |
| amiselimod hydrochloride Drug Profile | 74 | 2 |
| ATL-1102 Drug Profile | 76 | 5 |
| Cellular Immunotherapy for Relapsing Remitting Multiple Sclerosis Drug Profile | 81 | 1 |
| CHS-131 Drug Profile | 82 | 2 |
| cladribine Drug Profile | 84 | 3 |
| COG-133 Drug Profile | 87 | 2 |
| daclizumab Drug Profile | 89 | 6 |
| diazoxide Drug Profile | 95 | 2 |
| dimethyl fumarate Drug Profile | 97 | 2 |
| Gene Therapy for Relapsing and Remitting Multiple Sclerosis Drug Profile | 99 | 1 |
| glatiramer acetate ER Drug Profile | 100 | 1 |
| GNbAC-1 Drug Profile | 101 | 3 |
| GSK-239512 Drug Profile | 104 | 1 |
| guanabenz Drug Profile | 105 | 1 |
| HR-411 Drug Profile | 106 | 1 |
| hydralazine hydrochloride Drug Profile | 107 | 1 |
| IB-MS Drug Profile | 108 | 1 |
| imilecleucel-T Drug Profile | 109 | 5 |
| immune globulin (human) Drug Profile | 114 | 3 |
| inebilizumab Drug Profile | 117 | 2 |
| interferon beta-1b Drug Profile | 119 | 1 |
| interferon beta-1b Drug Profile | 120 | 1 |
| itolizumab Drug Profile | 121 | 2 |
| laquinimod sodium Drug Profile | 123 | 8 |
| M-2736 Drug Profile | 131 | 2 |
| masitinib Drug Profile | 133 | 14 |
| ofatumumab Drug Profile | 147 | 8 |
| opicinumab Drug Profile | 155 | 3 |
| Pegylated Interferon-Beta-1b Drug Profile | 158 | 1 |
| ponesimod Drug Profile | 159 | 2 |
| siponimod Drug Profile | 161 | 3 |
| Small Molecule to Target CTLA4 and IFNGR for RRMS Drug Profile | 164 | 1 |
| ublituximab Drug Profile | 165 | 7 |
| Xemys Drug Profile | 172 | 1 |
| Relapsing Remitting Multiple Sclerosis (RRMS) Dormant Projects | 173 | 2 |
| Relapsing Remitting Multiple Sclerosis (RRMS) Discontinued Products | 175 | 1 |
| Relapsing Remitting Multiple Sclerosis (RRMS) Product Development Milestones | 176 | 14 |
| Featured News &Press Releases | 176 | 1 |
| Sep 19, 2016: Active Biotech update on laquinimod Development: The U.S, Food and Drug administration rescinds the Special Protocol Assessment for laquinimod | 176 | 1 |
| Sep 12, 2016: Merck Presents New Data on the Safety and Durable Efficacy of Cladribine Tablets at the 2016 ECTRIMS Congress | 176 | 1 |
| Sep 08, 2016: Biogen To Present Data on Opicinumab (Anti-LINGO-1) at the 32nd congress of the European Committee for Treatment and Research in Multiple Sclerosis | 177 | 1 |
| Aug 01, 2016: RedHill Announces Last Patient Visit in Phase IIa Study with RHB-104 for Multiple Sclerosis | 178 | 1 |
| Jul 18, 2016: Merck Receives European Medicines Agency Acceptance for Review of Marketing Authorization Application for Cladribine Tablets | 179 | 1 |
| Jun 28, 2016: Coherus Announces Positive Phase 2B Efficacy Data On Novel Oral Therapy In Relapsing Remitting Multiple Sclerosis | 179 | 1 |
| Jun 17, 2016: Antisense Therapeutics provides update on ATL1102 for Multiple Sclerosis | 180 | 1 |
| May 31, 2016: GeNeuro Announces First Patients Treated in Phase 2b Study for Multiple Sclerosis | 181 | 1 |
| May 25, 2016: Merck to Present Data on Cladribine Tablets for Multiple Sclerosis at 2nd Congress of the European Academy of Neurology | 182 | 1 |
| May 03, 2016: TG Therapeutics Launches First Clinical Trial in Multiple Sclerosis (MS) for TG-1101 (Ublituximab) | 183 | 1 |
| Apr 22, 2016: Daclizumab Demonstrates Significant, Sustained Improvements In Cognition Compared To Interferon Beta-1A IM | 183 | 1 |
| Apr 20, 2016: Data Presented at AAN Highlight Impact of ZINBRYTA (Daclizumab HYP) on Cognitive Outcomes and the Reversibility of Its Targeted Mechanism of Action | 184 | 2 |
| Apr 12, 2016: Teva to Present Data on laquinimod at 68th AAN Annual Meeting | 186 | 1 |
| Apr 01, 2016: PJSC Pharmsynthez Completes Follow Up and Data Analysis From a Phase 2 Study of Novel Therapeutic Vaccine Xemys for Multiple Sclerosis | 187 | 1 |
| Mar 31, 2016: RedHill Announces Interim Results from Phase IIa PoC Study Supporting Therapeutic Potential of RHB-104 in Multiple Sclerosis | 187 | 3 |
| Appendix | 190 | 2 |
| Methodology | 190 | 1 |
| Coverage | 190 | 1 |
| Secondary Research | 190 | 1 |
| Primary Research | 190 | 1 |
| Expert Panel Validation | 190 | 1 |
| Contact Us | 190 | 1 |
| Disclaimer | 191 | 1 |